Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Amplia Therapeutics ( (AU:ATX) ) has provided an update.
Amplia Therapeutics is expanding its U.S. presence by increasing investor engagement and awareness through a capital markets campaign. This initiative supports its ongoing Phase 2A clinical trial for pancreatic cancer and includes plans to uplist to the OTCQB market, aiming to broaden its U.S. investor base and enhance its market positioning.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers, such as pancreatic and ovarian cancer, and chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 3,322,538
Technical Sentiment Signal: Hold
Current Market Cap: A$69.26M
Learn more about ATX stock on TipRanks’ Stock Analysis page.